



"BIOLOGIE PROSPECTIVE" SANTORINI CONFERENCES

<http://biol.prospective-conf.u-nancy.fr>

Second Santorini Conference
**FROM HUMAN GENETIC VARIATIONS TO PREDICTION OF
RISKS AND RESPONSES TO THE ENVIRONMENT**

**3rd Annual Meeting of the International Society of
Pharmacogenomics (ISP)**

Preliminary programme

Friday 1 October

Opening lectures

- Human population genetics, evolution and disease
L. Cavalli Sforza (Stanford University School of Medicine, Stanford, USA)
- Mitochondrial DNA diversity in health and diseases
D.C. Wallace (University of California, Irvine, USA)
- Genetic risks prediction.
A. Roses (GlaxoSmithKline, NC Research Triangle Park, USA)
- Pharmacogenomics and "individualized drug therapy": exciting challenges that remain ahead
D. Nebert (University of Cincinnati, Cincinnati, USA)

Cardiovascular diseases: predisposition genes and polymorphisms

- From Genotypes to phenotypes in cardiovascular risk assessment
F.Cambien (Inserm U.525, Hôpital Pitié Salpêtrière, Paris, France)
- DNA and RNA profiling in cardiovascular diseases
C.C. Liew (Harvard Medical School, Boston, USA)
- Useful Polymorphisms in the Stanislas Cohort study
S. Visvikis (Inserm U525, Université Henri Poincaré Nancy 1, Nancy, France)
- Useful polymorphisms in the Framingham studies
J.M. Ordovas (Tufts University, Boston, USA)
- Familial Hypercholesterolemia in Europe
G. Dedoussis (Harokopio University of Athens, Kallithea, Greece)
- The use of transgenic animals for studying polymorphisms related to cardiovascular diseases
MH. Hofker (University of Maastricht, Maastricht, The Netherlands)
- Predisposing genes linked to obesity
L. Peltonen-Palotie (National Public Health Institute, Helsinki, Finland)
- Muscle-dedicated chips for cardiovascular diseases
J. Léger (Inserm U.533, Ouest Génopole, Nantes, France)

Saturday 2 October

Cardiovascular drugs and pharmacogenomics

- Pharmacogenomics of drugs involved in cardiovascular diseases
G. Siest (INSERM U525, Nancy, France)
- Searching for SNP profiles for pharmacogenetics of hypertension
A.C. Syvänen (Uppsala University, Uppsala, Sweden)
- Cardiovascular Pharmacogenomics - Update 2004
B. Winkelmann (University of Heidelberg, Heidelberg, Germany)
- Pharmacogenomics and the therapeutical response to statins
A. Carrié (CHU Pitié Salpêtrière, Paris, France)
- Are we ready for pharmacogenomics in heart failure?
P. Charron (CHU Pitié Salpêtrière, Paris, France)
- The interface between nutrigenomics and pharmacogenomics in atherosclerosis prevention
R.M. Krauss (Oakland Research Institute, Oakland, USA)

Nutrigenomics (ecogenomics)

- Transposons and imprinted genes: Epigenomic targets linking prenatal nutrition to adult disease
R. Jirtle (Duke University Medical Center, Durham, USA)
- Folic Acid Intake and of MTHFR polymorphism in Egyptian mothers of children with Down syndrome
N.A. Meguid (National Research Center, Cairo, Egypt)
- The omega-6/omega-3 essential fatty acid ratio: Genetic variation of dietary response
A. Simopoulos (The Center for Genetics, Nutrition and Health, Washington, USA)
- Gene environment interaction (i.e.: exercise). Physical Activities
M.
- Alcohol and gene interactions
J. Whitfield (Royal Prince Alfred Hospital , Sydney, Australia)
- Metabolomics, genomics, diet and health
M.A. Roberts (Nestle Research Center, Lausanne, Switzerland)

FORUM

**EDUCATION FOR PHARMACOGENOMICS
NEEDS FOR CLINICIANS HEALTH SPECIALISTS AND PATIENTS**

F. Frueh (Stepoutside Consulting, USA)
D. Gurwitz (Tel Aviv University Tel Aviv, Israel)
F. Torricelli (Azienda Ospedaliera Careggi, Firenze, Italy)
C. Verstuyft (CHU Bicêtre, Le Kremlin Bicêtre, France)

Sunday 3 October

Cancer predisposition genes biomarkers and polymorphisms

- Molecular analysis of cancer using DNA and protein arrays
S. Hanash (University of Michigan, Ann Arbor, USA)
- Multiplex detection of mutation and cancer development
M. Makrigiorgios (Harvard Medical School, Boston, USA)
- Xenobiotic metabolising enzymes polymorphisms and cancer risk
E. Taioli (Ospedale Policlinico IRCCS , Milano, Italy)
- CYP2A6 polymorphism and tobacco related cancer
T. Kamataki (Hokkaido University, Sapporo, Japan)
- Clinical applications of proteomics
D. Chan (Biomarker Discovery Center, Baltimore, USA)
- Messenger mRNAs and leukemias: Diagnosis, follow up and therapy monitoring
F. Salvatore (University of Napoli Federico II, Napoli, Italy)

Anti-cancer drugs and pharmacogenomics

- Implications of acquired mutations on therapeutic response and drug resistance
S. Lilleberg (Transgenomic, Gaithersburg, Maryland, USA)
- A proteomic approach to chemoresistance in the squamous cell carcinoma cell line A431 treated with cisplatin
P.G. Righetti (University of Verona, Verona, Italy)
- Pharmacogenetics and oncology
M.

Pharmacogenomics drug metabolising enzymes

- Genetic regulation of nuclear receptors
M.
- Main CYP polymorphisms implicated in drug metabolism
Ph. Beaune (INSERM U 490, Centre Universitaire des Saints Pères, Paris, France)
- Aldehyde deshydrogenases polymorphisms
V. Vasiliou (University of Colorado, Denver, USA/Greece)

Monday 4 October

Drug or endobiotc metabolism and pharmacogenetics

- CYP2D6 xenobiotic and endobiotic substrates responses
J. Kirchheiner (University of Bonn, Bonn, Germany)
- ABC transporters polymorphisms, xenobiotic and endobiotic substrates responses
G. Schmitz (University of Regensburg, Germany)
- Targeted cells therapies and cancer pharmacogenomics
R. Pasqualini (University of Texas M. D. Anderson Cancer Center, Texas, USA)
- Integration of preclinical and clinical pharmacogenomics in drug development.
J. Vonderscher (Novartis Institutes for Biomedical Research, Inc., Cambridge, USA)

Pharmacogenomics of neurological and psychiatric disorders

- Depression and cardiovascular disease. Shared genetic substrates
J. Licinio (David Geffen School of Medicine at UCLA, Los Angeles, USA)
- Adrenergic receptor polymorphisms
C. Flordellis (University of Patras, Rion Patras, Greece)
- Pharmacogenomics enriched pain management
S. Wong (Medical College of Wisconsin, Wisconsin, USA)
- Pharmacogenetics and schizophrenia
J. Ioannidis (University of Ionnina, Ionnina, Greece)

CLOSING SESSION FROM GENOMICS TO PROTEOMICS

- Pharmacoproteomics
H. Langen (Roche, Basel, Switzerland)
- Proteomics in neurosciences
E. Wanker (Max Delbrück Center for Molecular Medicine, Berlin, Germany)